GlassScriptPhysician profile
Nutan K Parikh
NPI 1407933781
$9,656.98
in general payments reported to CMS, 2019-2025
62 companies · $1,882 in 2025
The $1,882 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $105 · 2021: $253 · 2022: $1,248 · 2023: $3,047 · 2024: $2,669 · 2025: $1,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,073 · Long Term Medical Supply Or Device Loan: $299 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,073.03 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $225.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,161.83 | 2022-2025 | |
| Janssen Biotech, INC. | $698.16 | 2022-2025 | Rybrevant, Darzalex, Carvykti |
| Merck Sharp & Dohme LLC | $562.95 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $513.89 | 2022-2025 | |
| Amgen INC. | $490.22 | 2019-2023 | Lumakras, Vectibix, Nplate |
| Glaxosmithkline, LLC. | $419.50 | 2022-2025 | Zejula, Ojjaara, Blenrep |
| Celgene Corporation | $402.74 | 2022-2024 | Reblozyl, Pomalyst |
| Incyte Corporation | $364.92 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genentech USA, INC. | $291.31 | 2021-2025 | Venclexta, Tecentriq, Phesgo |
| Exelixis INC. | $268.34 | 2019-2024 | Cabometyx |
| Emd Serono, INC. | $265.71 | 2022-2025 | Bavencio |
| Astrazeneca Pharmaceuticals LP | $259.58 | 2024-2025 | Imfinzi |
| Seagen INC. | $231.12 | 2021-2023 | Adcetris |
| E.R. Squibb & Sons, L.L.C. | $230.53 | 2019-2025 | Opdivo |
| Sobi, INC | $211.48 | 2024 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $200.66 | 2022-2025 | |
| Gilead Sciences, INC. | $186.69 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $185.72 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Lilly USA, LLC | $185.33 | 2019-2025 | Jaypirca, Verzenio |
| Takeda Pharmaceuticals U.S.A., INC. | $173.69 | 2019-2025 | Iclusig, Vpriv, Alunbrig |
| Alexion Pharmaceuticals, INC. | $157.37 | 2022-2024 | Ultomiris |
| Boston Scientific Corporation | $150.20 | 2023 | Icefx Cryoablation System |
| Springworks Therapeutics, INC. | $140.07 | 2024-2025 | Ogsiveo |
| Array Biopharma INC | $116.67 | 2023-2025 | Lorbrena, Mektovi, Braftovi |
| Mirati Therapeutics, INC. | $115.29 | 2023-2024 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $103.26 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $99.99 | 2023 | Fotivda |
| Sumitomo Pharma America, INC. | $98.07 | 2023-2025 | Orgovyx |
| Pharmacosmos Therapeutics INC. | $95.78 | 2022-2023 | Monoferric |
| Immunocore Limited | $89.95 | 2024-2025 | Kimmtrak |
| Regeneron Healthcare Solutions, INC. | $77.74 | 2023-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $75.17 | 2023 | Imbruvica |
| Abbvie INC. | $74.70 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $64.72 | 2023-2025 | Yonsa, Odomzo |
| Syndax Pharmaceuticals, INC. | $58.21 | 2025 | |
| Beigene USA, INC. | $56.71 | 2024-2025 | Tevimbra, Brukinsa |
| Kite Pharma, INC. | $54.48 | 2025 | Yescarta |
| Astellas Pharma US INC | $49.84 | 2022-2023 | Padcev, Xospata |
| Servier Pharmaceuticals LLC | $48.97 | 2024 | |
| Tempus Ai, INC | $46.93 | 2024 | |
| Azurity Pharmaceuticals, INC. | $46.73 | 2024-2025 | Danziten, Vivimusta |
| Taiho Oncology, INC. | $45.53 | 2022-2023 | |
| Genmab U.S., INC. | $43.47 | 2023-2024 | Epkinly, Tivdak |
| Ipsen Biopharmaceuticals, INC | $39.54 | 2022-2024 | Tazverik |
| Rigel Pharmaceuticals, INC. | $39.00 | 2022-2023 | Tavalisse, Rezlidhia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.36 | 2023 | Gilotrif |
| Spectrum Pharmaceuticals INC. | $28.01 | 2023 | Rolvedon |
| Iovance Biotherapeutics, INC. | $27.83 | 2025 | Amtagvi |
| Karyopharm Therapeutics INC. | $27.70 | 2023 | Xpovio |
| Octapharma USA, INC. | $26.08 | 2024 | Octagam Immune Globulin (Human) |
| Janssen Pharmaceuticals, INC | $25.72 | 2024 | |
| Novocure INC. | $22.26 | 2024 | Optune Lua (Novottf-200t) |
| Recordati_rare_diseases_inc. | $22.19 | 2023 | Sylvant |
| Stemline Therapeutics INC. | $21.58 | 2023 | Elzonris |
| Apellis Pharmaceuticals, INC. | $20.46 | 2024 | Empaveli |
| Coherus Oncology, INC. | $18.37 | 2023 | |
| Deciphera Pharmaceuticals INC. | $17.21 | 2023 | Qinlock |
| Myovant Sciences INC. | $16.96 | 2022 | |
| Pharmaessentia USA Corporation | $16.13 | 2023 | Besremi |
| Jazz Pharmaceuticals INC. | $15.48 | 2023 | |
| Tersera Therapeutics LLC | $14.90 | 2024 | Xermelo |
| Shield Therapeutics INC | $13.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nutan Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.